Bioimmune Systems of Salt Lake City said Thursday it reported to the Securities andExchange Commission (SEC) that it effected a 1-for-100 reverse stock split, effectiveMarch 22.

The company, which specialized in immune system strengthened drugs, said it hopes toraise the value of its stock to meet NASDAQ listing requirements, according to an SECfiling.